Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC Launches Simponi in Indonesia
September 21, 2012
- Nichi-Iko to Set Up New Sections in Sales, Development Divisions to Enhance Oncology Field
September 21, 2012
- Nippon Shinyaku Files for Additional Indication of Chronic Pain for Tramal Capsule
September 21, 2012
- Chugai Applies for Avastin for Recurrent Glioblastoma
September 21, 2012
- Astellas, KEK Announce Collaboration to Develop New Drugs for NTDs
September 21, 2012
- Intellim Establishes Local Office in South Korea, Set to Realize Asian Studies
September 20, 2012
- TS-1 Shows Non-Inferiority to Gemcitabine in Effect on Resected Pancreatic Cancer: Taiho
September 20, 2012
- Symptoms of Cedar Pollen Allergy Reduced in PIII Trial for Sublingual Immunotherapy Drug: Torii
September 20, 2012
- Kitasato Daiichi Sankyo Vaccine to Discontinue Animal Vaccine, to Focus on Human Vaccines
September 20, 2012
- Maruho to Acquire Shares of Maeda Pharmaceutical through Third-Party Allocation
September 20, 2012
- 72% of GPs, 41% of Hospital Doctors Issue Generic Name Prescriptions After April: Sawai Survey
September 20, 2012
- DSP Launches Latuda in Canada
September 19, 2012
- Eli Lilly Japan Applies for Strattera Oral Solution
September 19, 2012
- 60% of Sales to Come from Specialty Field, Oncology by 2017: President Mitani of Novartis Pharma
September 19, 2012
- Janssen Pharmaceutical Discontinues PII Study for Atopic Dermatitis Treatment in Japan
September 19, 2012
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
- MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor
September 19, 2012
- Teva Appoints Itzhak Krinsky as Chairman for Japan, South Korea
September 18, 2012
- Chugai Provides All-Case PMS Data via iPad, Beginning with Avastin
September 18, 2012
- Kaketsuken Starts PIII Trial for Cell-Culture-Based New-Type Influenza Vaccine
September 18, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…